Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | BHMT | Q93088 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23849153 | 0.79 | LTA4H (0.46) | LTA4HCHRNB2CHRNB4CHRNA4KMT2A | |
| SCHEMBL25184306 | 0.79 | LTA4H (0.46) | LTA4HCHRNB2CHRNB4CHRNA4KMT2A | |
| SCHEMBL2446304 | 0.78 | LTA4H (0.41) | LTA4HCHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL4603026 | 0.78 | LTA4H (0.41) | LTA4HCHRNB2CHRNA4MEN1KMT2A | |
| SCHEMBL2443555 | 0.78 | PIK3CD (0.40) | LTA4HBHMTCHRNB2CHRNB4CHRNA4 | |
| Hydrochloric Acid SCHEMBL2445583 | 0.77 | LTA4H (0.40) | LTA4HCHRNB2CHRNA4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2445581 | 0.77 | LTA4H (0.40) | LTA4HCHRNB2CHRNA4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2443556 | 0.77 | MEN1 (0.39) | LTA4HCHRNB2CHRNB4CHRNA4MEN1 | |
| Hydrochloric Acid SCHEMBL2443554 | 0.77 | MEN1 (0.39) | LTA4HCHRNB2CHRNB4CHRNA4MEN1 | |
| SCHEMBL11776470 | 0.73 | SMN1; SMN2 (0.42) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028658-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | ITGB6, ITGAV, ITGA6 | LTA4H 2249/4885BHMT 3878/4885CHRNB2 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.